Ann Gils

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 859 citations

Trough Concentrations, Inflammation, Anti-inflammatory +5

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

Niels Vande Casteele, Ann Gils, Sharat Singh et al. · The American Journal of Gastroenterology · 2013 · 342 citations

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Geert D’Haens, Séverine Vermeire, Guy Lambrecht et al. · Gastroenterology · 2018 · 295 citations · Full text

Inflammation, Chronic Inflammatory Diseases, Infliximab Dose +8

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Niels Vande Casteele, Reena Khanna, Barrett G. Levesque et al. · Gut · 2014 · 283 citations · Full text

The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

Laetitia Devy, Silvia Blacher, Christine Grignet‐Debrus et al. · The FASEB Journal · 2002 · 281 citations

Pharmacotherapy, Cellular Physiology, Tumor Biology +20